Group 1 - The company announced plans to acquire 19 health check institutions, increasing its control over these entities to 100% for 18 of them and 90% for one [1] - The total unaudited revenue for these 19 institutions in 2024 is projected to be 505 million, with a net profit of 52 million, resulting in a net profit margin of 10.26% [2] - The acquisition is expected to enhance the company's performance by increasing the number of controlled outlets and overall revenue [2] Group 2 - The company has initiated a comprehensive transformation since 2020, focusing on building a health industry ecosystem and has proposed an "All in AI" strategy in 2023 [2] - The company utilizes AI as a core tool to develop a digital management platform for health check services, enhancing the quality management system across the entire process [2] - The company has introduced innovative products targeting key medical disciplines, particularly in cancer early screening, to meet deep health check demands [2] Group 3 - The company has not adjusted its profit forecasts due to the unaudited performance of the acquired institutions, with projected revenues for 2024-2026 being 10.599 billion, 11.614 billion, and 12.731 billion respectively [3] - Expected net profits for 2024-2026 are projected to be 349 million, 562 million, and 798 million respectively, with growth rates of -31.0%, 61.2%, and 42.0% [3] - The corresponding price-to-earnings ratios for 2025-2026 are estimated to be 38 and 27 times, maintaining a "buy" rating [3]

智通财经4月14日电，美年健康(002044.SZ)公告称，公司拟通过发行股份的方式购买衡阳美年等14家公 司股权以及郑州美健等5家控股子公司的少数股权。本次交易上市公司拟收购多家标的公司股权，标的 公司均为上市公司参股或控股的体检中心，主营业务为提供健康体检服务，本次交易属于公司原有业务 的扩展。本次交易的具体交易价格尚未确定。本次交易完成后，上市公司将直接及间接持有衡阳美年、 宁德美年、烟台美年、烟台美年福田、武汉奥亚、三明美年、肥城美年、南宁美元康、德州美年、连江 美年、沂水美年、山东奥亚、厦门银城美年、郑州美健、花都美年、安徽美欣、淄博美年、吉林昌邑美 年100.00%及安溪美年90.00%股权。 美年健康：拟发行股份购买19家上市公司参股或控股的体检中心 ...